Stereotaxis Computed Tomography (CT) Co-Registration Study
Primary Purpose
Coronary Artery Disease
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Percutaneous coronary intervention
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Percutaneous Coronary Intervention, Magnetic Navigation, Computed Tomography
Eligibility Criteria
Inclusion Criteria:
- Patients must be between 18-80 years of age
- Willing and able to provide prior written informed consent
- Patients present with a single bifurcated lesion or single non-CTO complex lesion requiring PCI.
- Able to be safely exposed to magnetic fields, such as magnetic resonance imaging (MRI)
- CT angiography performed prior to cardiac catheterization (must be performed >48 hours prior to procedure to limit peri-procedural contrast use, but <12 months prior to the procedure)
Exclusion Criteria:
- Patients with a creatinine greater than 2.0 mg/dL
- Exclude patients whom in the Investigator's opinion, are hemodynamically unstable on the day of the procedure.
- Untreatable allergy to contrast media
- Patients who have undergone CT angiography within 48 hours of index PCI procedure
- Patients with chronic total occlusions (CTOs) requiring intervention.
- Patients requiring treatment for lesions other than the single bifurcated or single non-CTO complex lesion.
Sites / Locations
- New York Presbyterian Hospital-Columbia Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Group A-CT Coregistration
Group B-Angiographic
Group C-Standard Angiography
Arm Description
5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
5 subjects with standard angiography in a conventional PCI (Group C)
Outcomes
Primary Outcome Measures
The primary endpoint is to compare and evaluate the total contrast use between Groups A, B and C .
Secondary Outcome Measures
The secondary endpoint is to compare and evaluate the following data points between Groups A, B and C: fluoroscopy time, procedure time, crossing time, procedural contrast use, adverse events (AEs): e.g. clinically significant perforations
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00994331
Brief Title
Stereotaxis Computed Tomography (CT) Co-Registration Study
Official Title
Randomized Feasibility Study Comparing the Clinical Utility of the Stereotaxis Navigant™ Computed Tomography Angiography Importation and Co- Registration Feature, the NaviView™ Assisted Navigation Feature, and Standard Angiography
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Terminated
Why Stopped
Study terminated due to lack of enrollment.
Study Start Date
October 2009 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Stereotaxis
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The Stereotaxis Niobe® II Magnetic Navigation System (MNS) is designed to direct and digitally control catheter and guidewire based therapeutic and diagnostic devices along complex trajectories within the heart and coronary vasculature.
Navigation using vectors acquired from the CT Co-registration feature of Navigant™ provides clinical benefits for percutaneous coronary intervention (PCI) by decreasing the amount of contrast used during complex PCI procedures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Percutaneous Coronary Intervention, Magnetic Navigation, Computed Tomography
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group A-CT Coregistration
Arm Type
Active Comparator
Arm Description
5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
Arm Title
Group B-Angiographic
Arm Type
Active Comparator
Arm Description
5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
Arm Title
Group C-Standard Angiography
Arm Type
Active Comparator
Arm Description
5 subjects with standard angiography in a conventional PCI (Group C)
Intervention Type
Procedure
Intervention Name(s)
Percutaneous coronary intervention
Intervention Description
non surgical procedure to open blocked coronary arteries
Primary Outcome Measure Information:
Title
The primary endpoint is to compare and evaluate the total contrast use between Groups A, B and C .
Time Frame
6 months
Secondary Outcome Measure Information:
Title
The secondary endpoint is to compare and evaluate the following data points between Groups A, B and C: fluoroscopy time, procedure time, crossing time, procedural contrast use, adverse events (AEs): e.g. clinically significant perforations
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must be between 18-80 years of age
Willing and able to provide prior written informed consent
Patients present with a single bifurcated lesion or single non-CTO complex lesion requiring PCI.
Able to be safely exposed to magnetic fields, such as magnetic resonance imaging (MRI)
CT angiography performed prior to cardiac catheterization (must be performed >48 hours prior to procedure to limit peri-procedural contrast use, but <12 months prior to the procedure)
Exclusion Criteria:
Patients with a creatinine greater than 2.0 mg/dL
Exclude patients whom in the Investigator's opinion, are hemodynamically unstable on the day of the procedure.
Untreatable allergy to contrast media
Patients who have undergone CT angiography within 48 hours of index PCI procedure
Patients with chronic total occlusions (CTOs) requiring intervention.
Patients requiring treatment for lesions other than the single bifurcated or single non-CTO complex lesion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Moses, MD
Organizational Affiliation
New York Presbyterian Hospital-Columbia Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Presbyterian Hospital-Columbia Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Stereotaxis Computed Tomography (CT) Co-Registration Study
We'll reach out to this number within 24 hrs